Company Preparing Response to DoD Request for Proposal for
Delivery of Up to 14 Million Additional Doses of BioThrax
ROCKVILLE, Md.--(BUSINESS WIRE)--June 27, 2007--Emergent
BioSolutions Inc. (NYSE:EBS), a biopharmaceutical company, announced
today that, pursuant to the terms of an amended contract with the U.S.
Department of Defense (DoD), it anticipates completing delivery of
900,000 doses of BioThrax(R) (Anthrax Vaccine Adsorbed) during the
quarter ending June 30, 2007 or shortly thereafter. The company
anticipates that, with these deliveries, second quarter revenues would
be approximately $20 million. The terms of the amended contract with
the DoD authorize delivery of BioThrax ahead of schedule.
The company is also preparing its response to a May 7, 2007
request for proposal from the DoD for a follow-on contract for the
supply of up to 14 million doses of BioThrax to the military for its
active immunization program. The request for proposal contemplates a
contract term of one base year and three option years.
"Emergent BioSolutions and the DoD have a longstanding
relationship and we are pleased to continue to provide doses of
BioThrax for the military's ongoing active immunization program," said
Fuad El-Hibri, chairman and chief executive officer of Emergent
BioSolutions. "By repeatedly fulfilling our commitments to the U.S.
Government, we continue to strengthen our reputation for
reliability--an essential element of a successful partnership with the
government. I am proud of our role in helping to protect our nation's
troops against biological threats."
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a biopharmaceutical company
dedicated to one simple mission--to protect life. We develop,
manufacture and commercialize immunobiotics, consisting of vaccines
and therapeutics that assist the body's immune system to prevent or
treat disease. Our biodefense business focuses on immunobiotics for
use against biological agents that are potential weapons of
bioterrorism and biowarfare. Our marketed product, BioThrax(R)
(Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S.
Food and Drug Administration for the prevention of anthrax infection.
Our commercial business focuses on immunobiotics for use against
infectious diseases and other medical conditions that have resulted in
significant unmet or underserved public health needs. More information
on the company is available at www.emergentbiosolutions.com.
Safe Harbor Statement
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Any
statements, other than statements of historical fact, including
statements regarding our strategy, future operations, future financial
position, future revenues, projected costs, prospects, plans and
objectives of management, including our expected revenue for the
second quarter of 2007, and any other statements containing the words
"believes", "expects", "anticipates", "plans", "estimates" and similar
expressions, are forward-looking statements. There are a number of
important factors that could cause the company's actual results to
differ materially from those indicated by such forward-looking
statements, including our performance under BioThrax sales contract
with the U.S. Department of Defense, including the timing of
deliveries under that contract; our ability to obtain new BioThrax
sales contracts with the U.S. government; our plans for future sales
of BioThrax; our plans to pursue label expansions and improvements for
BioThrax; our plans to expand our manufacturing facilities and
capabilities; the rate and degree of market acceptance and clinical
utility of our products; our estimates regarding expenses, future
revenue, capital requirements and needs for additional financing; and
other factors identified in the company's Quarterly Report on Form
10-Q for the quarter ended March 31, 2007 and subsequent reports filed
with the SEC. The company disclaims any intention or obligation to
update any forward-looking statements as a result of developments
occurring after the date of this press release.
CONTACT: Emergent BioSolutions Inc.
Robert G. Burrows
Vice President, Investor Relations
SOURCE: Emergent BioSolutions Inc.